Nama's AI scorecard currently rates Genmab A/S Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is GMAB's P/E ratio?

Genmab A/S trades at a trailing price-to-earnings ratio of 38.9.

When does GMAB report earnings?

Genmab A/S's next scheduled report is on Feb 16, 2027. Analysts expect EPS of $0.16.

What is the GMAB price target?

The median analyst price target from 10 analysts is $66.30, with a range of $48.00 – $80.00.

Is GMAB Shariah compliant?

Nama's AAOIFI-style screen reads Genmab A/S as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Genmab A/S (GMAB)

Healthcare · Biotechnology · NASDAQ

Genmab A/S (GMAB) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $32.98B, a trailing price-to-earnings ratio of 38.9 and a free-cash-flow yield of 3.4%. Over the most recent reported fiscal year, revenue grew 19.2% and free cash flow per share grew 11.6%. Nama's AI scorecard rates it Buy, 6.0 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 6.0/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +27.1% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-10.6%

How far the last close sits under the highest price of the past five years.

Market cap	$32.98B
Trailing P/E	38.9
Price / book	0.6
Price / sales	8.0
FCF yield	3.4%
Dividend yield	—
Gross margin	93.0%
Operating margin	32.3%
Net margin	19.1%
Revenue growth (YoY)	+19.2%
Revenue growth (3-yr annual)	+21.2%
EPS growth (YoY)	-1.7%
FCF/share growth (YoY)	+11.6%
Beta	0.7
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

GMAB earnings

Next report: Feb 16, 2027 (Q4 2026, EPS estimate $0.16). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.55	$0.35	+57.1%	$1.19B
Q2 2026	Aug 6, 2026	$0.49	$0.33	+48.5%	$1.16B
Q1 2026	May 7, 2026	$0.13	$0.19	-31.6%	$896.00M
Q4 2025	Feb 17, 2026	$0.21	$0.37	-43.2%	$1.06B

GMAB analyst price target

Median target $66.30 from 10 analysts, ranging $48.00 – $80.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
ROIV	Roivant Sciences	$28.08B	—

Explore live GMAB data on Nama Insights →

Recent Congressional trades

Genmab A/S trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Josh Gottheimer	House	Buy	$1,001 - $15,000	Feb 10, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Jan 14, 2025
Josh Gottheimer	House	Buy	$1,001 - $15,000	Aug 15, 2024
Josh Gottheimer	House	Sell	$1,001 - $15,000	Jul 9, 2024
Josh Gottheimer	House	Buy	$1,001 - $15,000	Nov 11, 2023
Josh Gottheimer	House	Sell	$1,001 - $15,000	Oct 15, 2023
Josh Gottheimer	House	Buy	$1,001 - $15,000	Aug 21, 2023
Josh Gottheimer	House	Buy	$1,001 - $15,000	Aug 21, 2023
Daniel Goldman	House	Sell	$50,001 - $100,000	Aug 13, 2023
Thomas R Carper	Senate	Buy	$1,001 - $15,000	—

GMAB FAQ

Is GMAB a buy?: Nama's AI scorecard currently rates Genmab A/S Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is GMAB's P/E ratio?: Genmab A/S trades at a trailing price-to-earnings ratio of 38.9.
When does GMAB report earnings?: Genmab A/S's next scheduled report is on Feb 16, 2027. Analysts expect EPS of $0.16.
What is the GMAB price target?: The median analyst price target from 10 analysts is $66.30, with a range of $48.00 – $80.00.
Is GMAB Shariah compliant?: Nama's AAOIFI-style screen reads Genmab A/S as Not Shariah Compliant. At least one of the three ratios or the industry test failed.